Fig. 8

SRGN modulates glycolysis and promotes the activation of microglia. A Relative intercellular glucose level of BV2 cells treated with rSRGN (50 ng/ mL, 6 h) or control solvent. B Relative level of L-Lactate production by BV2 cells treated with rSRGN (50 ng/ mL, 6 h) or control solvent. C Relative level of L-Lactate in ischemic mice brain 1 day after MCAO. The mice were injected with rSRGN (2.5 mg/ mL) or control solvent soon after MCAO. n = 4 mice per group. D The qPCR analysis of Hif1a mRNA level in primary microglia treated with rSRGN (50 ng/ mL, 6 h) or control solvent. E, F Representative immunoblot image (E) and quantification of HIF-1α protein level (F) in microglia treated with rSRGN (50 ng/ mL, 6 h) or control solvent. GAPDH served as the loading control. G, H Representative immunoblot image (G) and quantification of HIF-1α protein level (H) in the primary microglia extracted from neonatal Srgn-KO mice and their WT littermates, with or without LPS (100 ng/ mL, 6 h) induction. β-Actin served as the loading control. I The qPCR analysis of Il1b mRNA level in primary microglia treated with rSRGN (50 ng/ mL, 6 h), 2-DG (1 mM, 2 h before rSRGN) or a combination of both. Data represented as mean ± SEM, * p < 0.05, ** p < 0.01, ***p < 0.001, ns, no significant